Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease

Transplantation

Volumn 62, Issue 9, 1996, Pages 1278-1285

  Krenger, Werner ^a,c   Cooke, Kenneth R ^a   Crawford, James M ^b   Sonis, Stephen T ^b   Simmons, Ray ^b   Pan, Luying ^a   Delmonte Jr , John ^a   Karandikar, Mahesh ^a   Ferrara, James L M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 4; MINOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DONOR; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; MIXED LYMPHOCYTE REACTION; MORTALITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; INTERLEUKIN-4; MICE; MICE, INBRED CBA; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030472390     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199611150-00018     Document Type: Article

References (48)

1. Martin PJ, Kernan NA. T-cell depletion for the prevention of graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara JLM, Atkinson K, eds. Graft-vs. host disease. Immunology, pathophysiology, and treatment. New York: Marcel Dekker Inc., 1990: 371.
2. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011.
3. Piguet PF, Grau GE, Allet B, Vassalli PJ. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987; 166: 1280.
4. McCarthy PL, Abhyankar S, Neben S, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915.
5. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138.
6. Croft M, Carter L, Swain SL, Dutton RW. Generation of antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994; 180: 1715.
7. + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995; 155: 585.
8. Allen RD, Staley TA, Sidman CL. Differential cytokine expression acute and chronic murine graft-versus-host disease. Eur J Immunol 1993; 23: 333.
9. Via CS, Finkelman FD. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol 1993; 5: 565.
10. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 1992; 327: 1613.
11. Troutt AB, Kelso A. Enumeration of lymphokine mRNA-containing cells in vivo in a murine graft-versus-host reaction using the PCR. Proc Natl Acad Sci USA 1992; 89: 5276.
12. Mowat A. Antibodies to IFN-gamma prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunology 1989; 68: 18.
13. Piguet PF. Tumor necrosis factor and graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara JLM, Atkinson K, eds. Graft-vs. host disease. Immunology, pathophysiology, and treatment. New York: Marcel Dekker Inc., 1990: 258.
14. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405.
15. Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T-cells from marrow. J Exp Med 1978; 148: 1687.
16. Keever CA, Small TN, Flomenberg N, et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood 1989; 73: 1340.
17. Spitalny G, Havell E. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J Exp Med 1984; 159: 1560.
18. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR. Two types of mouse helper T cell clones: III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med 1987; 166: 1229.
19. Ohara J, Paul WE. Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature 1985; 315: 333.
20. Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 1992; 127: 5.
21. Marshak-Rothstein A, Fink P, Gridley T, Raulet DH, Bevan MJ, Gefter ML. Properties and applications of monoclonal antibodies directed against determinants of the Thy-1 locus. J Immunol 1979; 122: 2491.
22. Krenger W, Snyder K, Smith S, Ferrara JLM. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 1994; 58: 1251.
23. Ferrara J, Guillen FJ, Sleckman B, Burakoff SJ, Murphy GF. Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease. J Invest Dermatol 1986; 86: 371.
24. Blatter DD, Crawford JM, Ferrara JLM. Nuclear magnetic resonance of hepatic graft-versus-host disease in mice. Transplantation 1990; 50: 1011.
25. Fontaine P, Perreault C. Diagnosis of graft-versus-host disease in mice transplanted across minor histocompatibility barriers. Transplantation 1990; 49: 1177.
26. Holler E, Kolb HJ, Hintermeier-Knabe R, et al. The role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 1993; 25: 1234.
27. Jadus MR, Wepsic HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 1992; 10: 1.
28. Korngold R, Sprent J. Purified T cell subsets and lethal graft-versus-host disease in mice. In: Gale RP, Champlin R, eds. Progress in bone marrow transplantation. New York: Alan R. Liss, 1987: 213.
29. + T cell clones secrete the Th1 pattern of cytokines. J Immunol 1990; 144: 1744.
30. Holler E, Kolb HJ, Mittermueller J, et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood 1995; 86: 890.
31. Gifford GE, Lohmann-Matthes ML. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. J Natl Cancer Inst 1987; 78: 121.
32. Sher A, Gazzinelli RT, Oswald IP, et al. Role of T cell-derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev 1992; 127: 183.
33. Korngold R, Sprent J. T cell subsets in graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara JLM, Atkinson K, eds. Graft-vs. host disease. Immunology, pathophysiology, and treatment. New York: Marcel Dekker, 1990: 31.
34. + T cells secreting Th1 or Th2 cytokines. Immunity 1995; 2: 271.
35. + T helper type 2 cells. J Exp Med 1995; 181: 5.
36. Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol Today 1995; 16: 374.
37. Bacchetta R, Parkman R, McMahon M, et al. Dysfunctional cytokine production by host-reactive T-cell clones isolated from a chimeric severe combined immunodeficiency patient transplanted with haploidentical bone marrow. Blood 1995; 85: 1944.
38. Murphy E, Shibuya K, Hosken N, et al. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. J Exp Med 1996; 183: 901.
39. Guillen FJ, Ferrara J, Hancock WW, et al. Acute cutaneous graft-versus-host disease to minor histocompatibility antigens in a murine model. Evidence that large granular lymphocytes are effector cells in the immune response. Lab Invest 1986; 55: 35.
40. Hakim FT, Sharrow SO, Payne S, Shearer GM. Repopulation of host lymphohematopoietic systems by donor cells during graft-versus-host reaction in unirradiated adult F1 mice injected with parental lymphocytes. J Immunol 1991; 146: 2108.
41. Knobloch C, Dennert G. Asialo-GM1-positive T killer cells are generated in F1 mice injected with parental spleen cells. J Immunol 1988; 140: 744.
42. + T cell responses. Bone Marrow Transplant 1992; 9: 355.
43. Widmer MB, Grabstein KH. Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor. Nature 1987; 326: 795.
44. Thornhill MH, Wellicome SM, Mahiouz DL, Lanchbury JSS, Kyan-Aung U, Haskard DO. Tumor necrosis factor combines with IL-4 or IFN-γ to selectively enhance endothelial cell adhesiveness for T cells. J Immunol 1991; 146: 592.
45. Mueller KM, Jaunin F, Masouye I, Saurat JH, Hauser C. Th2 cells mediate IL-4-dependent local tissue inflammation. J Immunol 1993; 150: 5576.
46. Atkinson K, Matias C, Guiffre A, et al. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 1991; 77: 1376.
47. DeWit D, Van Mechelen M, Zanin C, et al. Preferential activation of Th2 cells in chronic graft-versus-host disease. J Immunol 1993; 150: 361.
48. Garlisi CG, Pennline KJ, Smith SR, Siegel MI, Umland SP. Cytokine gene expression in mice undergoing chronic graft-versus-host disease. Mol Immunol 1993; 30: 669.